 5. Subjects must be in good general health prior to study participation no more than 30 days prior to study vaccine administration with no clinically relevant abnormalities that could jeopardize subject safety or interfere with study assessments as assessed by the Principal Investigator or Sub-Investigator thereafter referred as Investigator and determined by medical history, physical examination, biochemistry, hematology, and urinalysis. 